Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Patients who added Cabometyx to Opdivo and Yervoy had a 27% lower risk of disease progression or death.
A unique analysis measures treatment-free survival after immunotherapy in patients with advanced renal cell carcinoma.
A new study sheds light on how cholesterol fills clear-cell renal cell carcinoma with cholesterol.
Targeted therapy and immunotherapy combination doubles response rate for people with advanced renal cell carcinoma.
In patients at high risk of relapse, adjuvant therapy with Keytruda prolonged disease-free survival.
The kinase inhibitor delayed disease progression by 27% for people who had tried at least two prior therapies.
Opdivo plus Cabometyx reduced the risk of death by 40%.
First-line Lenvima plus Keytruda yields better overall survival for patients with metastatic kidney cancer.
The immunotherapy combination slowed disease progression and reduced the risk of death by 40%.
MK-6482 shrank tumors in 24% of people with advanced renal cell carcinoma.
FDA approves immunotherapy plus targeted therapy combo for initial treatment of advanced renal cell carcinoma.
Ed Doelp lives with his wife, Dawn, in Smithville, New Jersey. Now in his 60s, he was diagnosed with kidney cancer in 2012.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.